The rate-cut trade is splitting in two: buy biotech, not every growth stock
A softer July PCE report could revive duration, but the best rebound candidates are profitable, catalyst-backed biotechs rather than every cash-burning growth stock. If inflation keeps yields high, JPM and Goldman offer the more defensible earnings-supported trade.
The July PCE report arriving with personal income and spending data on Aug. 26 could restart the rate-cut trade, but it should not restart the indiscriminate growth trade. The market is already drawing a line between biotech companies with current earnings and speculative names whose value depends on distant catalysts. Vertex and Regeneron sit on the favorable side of that line; banks such as JPMorgan and Goldman Sachs provide the alternative if inflation keeps yields elevated. The question is not whether to buy risk, but which form of duration or earnings resilience the data justify.
The recent relative strength in XBI and makes this a useful reframe. A soft PCE print would likely lower yields and improve the present value of future cash flows, helping long-duration assets. But the transmission will not be uniform. A company with revenue, margins, and a visible product catalyst can benefit from falling rates without requiring investors to suspend judgment on profitability. A cash-burning growth stock gets the rate benefit too, but it has fewer operating facts to support the rerating. That distinction matters more than the broad risk-on label attached to the trade.
VRTX is the clearest example of biotech duration with fundamentals. Recent market data put Vertex at 28.65x forward earnings, a premium to the banks, but its Q2 2026 revenue rose 12% year over year and management raised its 2026 sales guidance after the quarter. That is not merely a long-duration story. It is a profitable business with an operating trajectory that gives investors something to underwrite while they wait for a more favorable rate backdrop. If PCE cools, Vertex can receive a valuation lift; if it does not, its earnings base gives the stock a better defense than an unprofitable growth name.
REGN makes the valuation argument even more directly. A recent market snapshot showed Regeneron at 15.92x forward earnings, with a 29.65% profit margin and $3.27 billion in levered free cash flow. The point is not that a low multiple makes biotech immune to rate pressure or pipeline risk. It is that Regeneron’s current cash generation limits how much of the investment case rests on a distant terminal value. A rate-cut rally that favors quality should reward that profile, especially if investors become less willing to pay up for growth that has not yet converted into earnings.
That is why CRSP should not be treated as interchangeable with Vertex or Regeneron. CRISPR Therapeutics remains a high-upside catalyst vehicle, but its Aug. 2026 snapshot showed no trailing or forward P/E, just $10 million of Q2 revenue, and a $91.15 million quarterly loss. Those figures do not invalidate the science or the potential commercial opportunity. They do establish that CRSP is a speculation on future execution rather than a quality-growth compounder today. If the PCE report broadens appetite for duration, the market may lift CRSP as well, but that would be a higher-beta expression of the view, not the most defensible one.
The valuation comparison reinforces the split. Vertex’s 28.65x forward P/E is meaningfully above JPMorgan at 14.79x and Goldman Sachs at 15.50x, so biotech duration is not cheap relative to financial stocks. That premium can be justified by stronger growth and the possibility of product-led upside, but it also raises the burden of proof. Investors should not confuse a favorable sector setup with permission to ignore price. Regeneron’s 15.92x forward multiple, by contrast, sits much closer to the banks while retaining the biotech catalyst profile. The better rate-cut basket is therefore selective: pay a premium for durable growth when the operating evidence supports it, and prefer reasonable valuation when it does not.
If inflation stays sticky, the trade changes rather than disappears. JPMorgan reported $21.2 billion of Q2 net income, while Goldman Sachs delivered Q2 earnings per share of $20.98. Those are fresh earnings outcomes, not hypothetical benefits from a lower discount rate. Investment banking, trading, and healthy consumer credit helped JPMorgan produce its highest quarterly profit ever posted by a U.S. bank, and Goldman’s result shows the capital-markets side of finance can also generate momentum. Their forward multiples are lower than Vertex’s, which gives investors an earnings-supported way to stay exposed to market activity without relying on a broad decline in yields.
Yes, growth bulls would argue that a sufficiently soft PCE report can lift all long-duration assets, and mechanically they are right: lower real yields make distant cash flows more valuable. But that argument overlooks the starting point. The market is not choosing between equally mature companies; it is choosing between profitable biotech leaders, unprofitable catalyst names, and banks already producing substantial earnings. A sharp rate move could temporarily overwhelm those differences, but a durable rerating should favor the businesses that can show progress after the initial multiple expansion.
The counterargument to banks is also credible. JPMorgan and Goldman are not bargain-basement stocks, and an aggressive easing cycle could pressure parts of bank profitability as the yield curve and credit conditions adjust. That is why banks are not a substitute for biotech in every scenario. They are the cleaner alternative if the July data fail to validate lower rates, because their investment case is tied to recent profits, capital-markets activity, and consumer credit rather than to a promise that valuation will expand. The relative-value choice is therefore asymmetric: biotech gains from a softer inflation path, while banks can remain supported if that path does not appear.
The market’s next move should be judged by breadth and quality together. If XBI continues to outperform while the strongest gains remain concentrated in profitable names such as Vertex and Regeneron, the signal is constructive for catalyst-backed biotech rather than for growth stocks as a whole. If XLF holds its relative strength as yields stay elevated, that would confirm that earnings resilience is competing effectively with duration. CRSP’s performance may tell us how much speculation is returning, but it should not decide whether the broader thesis is sound. The important distinction is between a falling-rate trade and a blanket invitation to buy every long-duration asset.
We favor biotech, but not biotech indiscriminately: Vertex offers the strongest combination of growth and current profitability, while Regeneron provides the more valuation-disciplined expression. JPMorgan and Goldman Sachs are the better relative-value choice if July PCE, income, and spending keep the market leaning toward higher-for-longer rates. We would become more constructive on speculative growth only if the data were followed by a visible improvement in earnings support, not merely a temporary drop in yields.
Our take, not advice. This is opinion commentary — informational only, not personalized investment recommendations. Markets carry risk. Do your own research and consider your own situation before any trade.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
